Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Late-Stage C-H Coupling Enables Rapid Identification of HDAC Inhibitors: Synthesis and Evaluation of NCH-31 Analogues.

Sekizawa H, Amaike K, Itoh Y, Suzuki T, Itami K, Yamaguchi J.

ACS Med Chem Lett. 2014 Mar 3;5(5):582-6. doi: 10.1021/ml500024s. eCollection 2014 May 8.

2.

Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells.

Sanda T, Okamoto T, Uchida Y, Nakagawa H, Iida S, Kayukawa S, Suzuki T, Oshizawa T, Suzuki T, Miyata N, Ueda R.

Leukemia. 2007 Nov;21(11):2344-53. Epub 2007 Aug 9.

PMID:
17690692
3.

Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.

Tashima T, Murata H, Kodama H.

Bioorg Med Chem. 2014 Jul 15;22(14):3720-31. doi: 10.1016/j.bmc.2014.05.001. Epub 2014 May 14.

PMID:
24864038
4.

Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6.

Scott GK, Marx C, Berger CE, Saunders LR, Verdin E, Schäfer S, Jung M, Benz CC.

Mol Cancer Res. 2008 Jul;6(7):1250-8. doi: 10.1158/1541-7786.MCR-07-2110.

5.

Synthesis and biological evaluation of novel FK228 analogues as potential isoform selective HDAC inhibitors.

Narita K, Matsuhara K, Itoh J, Akiyama Y, Dan S, Yamori T, Ito A, Yoshida M, Katoh T.

Eur J Med Chem. 2016 Oct 4;121:592-609. doi: 10.1016/j.ejmech.2016.05.031. Epub 2016 May 18.

PMID:
27318982
6.
7.

Cephalostatin analogues--synthesis and biological activity.

Flessner T, Jautelat R, Scholz U, Winterfeldt E.

Fortschr Chem Org Naturst. 2004;87:1-80. Review.

PMID:
15079895
8.

Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.

Hui KF, Chiang AK.

Int J Cancer. 2014 Dec 15;135(12):2950-61. doi: 10.1002/ijc.28924. Epub 2014 May 5.

9.

Differential regulation of Bdnf expression in cortical neurons by class-selective histone deacetylase inhibitors.

Koppel I, Timmusk T.

Neuropharmacology. 2013 Dec;75:106-15. doi: 10.1016/j.neuropharm.2013.07.015. Epub 2013 Aug 2.

PMID:
23916482
10.

Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform.

Blackburn C, Barrett C, Chin J, Garcia K, Gigstad K, Gould A, Gutierrez J, Harrison S, Hoar K, Lynch C, Rowland RS, Tsu C, Ringeling J, Xu H.

J Med Chem. 2013 Sep 26;56(18):7201-11. doi: 10.1021/jm400385r. Epub 2013 Sep 4.

PMID:
23964961
11.

Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes.

Bantscheff M, Hopf C, Savitski MM, Dittmann A, Grandi P, Michon AM, Schlegl J, Abraham Y, Becher I, Bergamini G, Boesche M, Delling M, Dümpelfeld B, Eberhard D, Huthmacher C, Mathieson T, Poeckel D, Reader V, Strunk K, Sweetman G, Kruse U, Neubauer G, Ramsden NG, Drewes G.

Nat Biotechnol. 2011 Mar;29(3):255-65. doi: 10.1038/nbt.1759. Epub 2011 Jan 23.

PMID:
21258344
12.

Synthesis and biological evaluation of histone deacetylase inhibitors that are based on FR235222: a cyclic tetrapeptide scaffold.

Singh EK, Ravula S, Pan CM, Pan PS, Vasko RC, Lapera SA, Weerasinghe SV, Pflum MK, McAlpine SR.

Bioorg Med Chem Lett. 2008 Apr 15;18(8):2549-54. doi: 10.1016/j.bmcl.2008.03.047. Epub 2008 Mar 20.

13.

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.

Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS, Sehested M.

Biochem J. 2008 Jan 15;409(2):581-9.

PMID:
17868033
14.

Rational design and diversity-oriented synthesis of peptoid-based selective HDAC6 inhibitors.

Diedrich D, Hamacher A, Gertzen CG, Alves Avelar LA, Reiss GJ, Kurz T, Gohlke H, Kassack MU, Hansen FK.

Chem Commun (Camb). 2016 Feb 21;52(15):3219-22. doi: 10.1039/c5cc10301k.

PMID:
26810607
15.

Synthesis and biological evaluation of largazole analogues with modified surface recognition cap groups.

Bhansali P, Hanigan CL, Perera L, Casero RA Jr, Tillekeratne LM.

Eur J Med Chem. 2014 Oct 30;86:528-41. doi: 10.1016/j.ejmech.2014.09.009. Epub 2014 Sep 6.

16.

Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects.

Vishwakarma S, Iyer LR, Muley M, Singh PK, Shastry A, Saxena A, Kulathingal J, Vijaykanth G, Raghul J, Rajesh N, Rathinasamy S, Kachhadia V, Kilambi N, Rajgopal S, Balasubramanian G, Narayanan S.

Int Immunopharmacol. 2013 May;16(1):72-8. doi: 10.1016/j.intimp.2013.03.016. Epub 2013 Mar 27.

PMID:
23541634
17.

Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).

Feng T, Wang H, Su H, Lu H, Yu L, Zhang X, Sun H, You Q.

Bioorg Med Chem. 2013 Sep 1;21(17):5339-54. doi: 10.1016/j.bmc.2013.06.009. Epub 2013 Jun 15.

PMID:
23820574
18.

Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages.

Hansen FK, Sumanadasa SD, Stenzel K, Duffy S, Meister S, Marek L, Schmetter R, Kuna K, Hamacher A, Mordmüller B, Kassack MU, Winzeler EA, Avery VM, Andrews KT, Kurz T.

Eur J Med Chem. 2014 Jul 23;82:204-13. doi: 10.1016/j.ejmech.2014.05.050. Epub 2014 May 22.

19.

Potent and selective HDAC6 inhibitory activity of N-(4-hydroxycarbamoylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorenes as novel sulfur analogues of Tubastatin A.

De Vreese R, Verhaeghe T, Desmet T, D'hooghe M.

Chem Commun (Camb). 2013 May 8;49(36):3775-7. doi: 10.1039/c3cc41422a. Epub 2013 Mar 28.

PMID:
23538448
20.

Synthesis of Potent and Selective HDAC6 Inhibitors Bearing a Cyclohexane- or Cycloheptane-Annulated 1,5-Benzothiazepine Scaffold.

De Vreese R, Galle L, Depetter Y, Franceus J, Desmet T, Van Hecke K, Benoy V, Van Den Bosch L, D'hooghe M.

Chemistry. 2017 Jan 1;23(1):128-136. doi: 10.1002/chem.201604167. Epub 2016 Nov 30.

PMID:
27717044

Supplemental Content

Support Center